Clinical study design

Abbott Launches the World's Smallest Implantable, Rechargeable Spinal Cord Stimulation System for Chronic Pain

Retrieved on: 
Monday, December 19, 2022
Virginias, Life, Pain, IPhone, Physician, Medical device, Quality of life, De Ridder, SCS, Hyperreflexia, NYSE, Parenteral nutrition, Chronic pain, Food, FDA, Comparison, Apple, BURST, Randomized controlled trial, Regulation of tobacco by the U.S. Food and Drug Administration, Skin, Clinical study design, XR, Spinal cord, Health, Eterna, NANS, Systematic review, Meta-analysis, Patient, Spine, Eucalyptus diversicolor, Deer, Proclaim!, MRI, Caregiver, Gauge (instrument), PMID, Electric battery, Dentistry, Pharmaceutical industry, Poultry, Brain

Clinically proven therapy: The Eterna SCS system features Abbott's proprietary BurstDR stimulation, which mimics natural firing patterns found in the brain7 to deliver superior**8 pain relief.

Key Points: 
  • Clinically proven therapy: The Eterna SCS system features Abbott's proprietary BurstDR stimulation, which mimics natural firing patterns found in the brain7 to deliver superior**8 pain relief.
  • "Eterna is the smallest rechargeable spinal cord stimulator on the market, provides the longest therapy between charges and offers an optimized recharging experience – all key features when selecting the best overall system.
  • For U.S. important safety information on the Abbott Eterna spinal cord stimulation system, visit: https://bit.ly/3Wgpude .
  • Comparison of Spinal Cord Stimulation Waveforms for Treating Chronic Low Back Pain: Systematic Review and Meta-Analysis.

Update: BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore

Retrieved on: 
Wednesday, December 14, 2022
Cleveland Clinic, Nautilus, Inc. v. Biosig Instruments, Inc., AF, Physician, Electrophysiology, Cardiac electrophysiology, Motion, Mayo Clinic, Security (finance), Associated, FDA, Journal, Trial of the century, Journal of Cardiovascular Electrophysiology, Risk, EGM, EST, Clinical study design, ECG, ST, EP, PURE, COVID-19, Patient, Medical imaging, Medical device, Pharmaceutical industry

Results from the randomized study reveal the PURE EP™ System’s potential to promote shorter procedural times and higher cost savings during catheter ablations.

Key Points: 
  • Results from the randomized study reveal the PURE EP™ System’s potential to promote shorter procedural times and higher cost savings during catheter ablations.
  • The primary objective was to determine the difference in procedural times when comparing ablations guided by PURE EP™’s electrocardiogram (EGM) visualization to the conventional ECG recording system.
  • Study results demonstrated that the PURE EP™ System led to a mean procedure time reduction of 11.3 minutes.
  • Given that the mean cost of operating room time is approximately $37 per minute1, the procedural time savings demonstrated by the PURE EP™ System suggest potential cost savings of approximately $418.10 per procedure.

BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore

Retrieved on: 
Wednesday, December 14, 2022
Cleveland Clinic, Nautilus, Inc. v. Biosig Instruments, Inc., AF, Physician, Electrophysiology, Cardiac electrophysiology, Motion, Mayo Clinic, Security (finance), Associated, FDA, Journal, Trial of the century, Journal of Cardiovascular Electrophysiology, Risk, EGM, EST, Clinical study design, ECG, ST, EP, PURE, COVID-19, Patient, Medical imaging, Medical device, Pharmaceutical industry

Results from the randomized study reveal the PURE EP™ System’s potential to promote shorter procedural times and higher cost savings during catheter ablations.

Key Points: 
  • Results from the randomized study reveal the PURE EP™ System’s potential to promote shorter procedural times and higher cost savings during catheter ablations.
  • The primary objective was to determine the difference in procedural times when comparing ablations guided by PURE EP™’s electrocardiogram (EGM) visualization to the conventional ECG recording system.
  • Study results demonstrated that the PURE EP™ System led to a mean procedure time reduction of 11.3 minutes.
  • Given that the mean cost of operating room time is approximately $37 per minute1, the procedural time savings demonstrated by the PURE EP™ System suggest potential cost savings of approximately $418.10 per procedure.

CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

Retrieved on: 
Thursday, December 8, 2022
Society, Security (finance), Randomness, Lymphoma, Form 10-K, Physician, Brain, Reata Pharmaceuticals, KPS, Glioblastoma, II, Cell proliferation, MD, MD Anderson Cancer Center, Central nervous system, Blood–brain barrier, University, Daunorubicin, Doctor of Philosophy, CNS, Fiat 500X, MGMT, Patient, BSA, DNA, Cancer, BBB, OS, Pakistan Society of Neuro-Oncology, Traffic barrier, Drug Quality and Security Act, Disease, FDA, Anthracycline, Multimedia, Clinical trial, Clinical study design, Safety, Risk, GBM, Doxorubicin, Medicinal chemistry, Pharmaceutical industry, Medical imaging, Lomustine

HOUSTON, Dec. 8, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced preliminary results from its ongoing potentially pivotal trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM).

Key Points: 
  • "Berubicin continues to demonstrate its ability to be an innovative treatment in GBM as a safe and potentially effective therapy.
  • These preliminary findings bolster our conviction in Berubicin as we continue to advance this study forward.
  • Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
  • CNS Pharmaceuticals is evaluating the use of the WP1244 portfolio in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.

Sama CEO Wendy Gonzalez Named 2022 Woman of the Year by Business Intelligence Group

Retrieved on: 
Tuesday, November 29, 2022
Professional Services, Education, Data Management, Business, Technology, Artificial Intelligence, Training, Randomized controlled trial, AI, Machine learning, Clinical study design, Medtech, Transport, Language, Business intelligence, B Corporation (certification), MIT, Agriculture, GM, Woman of the Year, Woman, Walmart, Business, Poverty, Algorithm, Medical device, Cryptocurrency, NVIDIA

Sama, the leader in providing high-quality training data for ambitious AI, announced today that CEO Wendy Gonzalez received the Business Intelligence Groups BIG Award for Business and was named Woman of the Year.

Key Points: 
  • Sama, the leader in providing high-quality training data for ambitious AI, announced today that CEO Wendy Gonzalez received the Business Intelligence Groups BIG Award for Business and was named Woman of the Year.
  • Im honored to have been named Woman of the Year by the Business Intelligence Group, said Gonzalez.
  • We are so proud to reward Wendy Gonzalez for her outstanding 2022 leadership and achievements, said Maria Jimenez, chief nomination officer of the Business Intelligence Group .
  • The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world.

Global Virtual Clinical Trials Global Market Report 2022: Increasing Adoption of Telehealth Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 9, 2022
Health, Clinical Trials, Investment, Cardiovascular disease, Clinical study design, Geography, Risk, Porter's five forces analysis, COVID-19, Ansoff Matrix, Market development, Observation, SWOT, Growth, Systolic Blood Pressure Intervention Trial, Industry, Dietary supplement, Pharmaceutical industry, Retail, Implication, Oncology

By Study Design, the market is classified into Expanded Access Trials, Interventional Trials, and Observational Trials.

Key Points: 
  • By Study Design, the market is classified into Expanded Access Trials, Interventional Trials, and Observational Trials.
  • The report presents a detailed Ansoff matrix analysis for the Global Virtual Clinical Trials Market.
  • The analyst analyses the Global Virtual Clinical Trials Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Virtual Clinical Trials Market.

Medicare Issues Final Rule that Increases Payment Rates for iTind Procedure Performed in Outpatient Settings

Retrieved on: 
Thursday, November 3, 2022
Man, Patient, Prospective payment system, OPPS, BPH, Health care, Science, Ageing, Medicare, Multimedia, UNITE, Elective surgery, Endoscopy, Centers for Medicare & Medicaid Services, Urination, Olympus, PMID, Laparoscopy, Quality of life, FACS, Olympus Corporation, Center, LUTS, Urine, APC, Hotlines, Clinical study design, CMS, ASC, Technology, MBA, Urinary tract infection, Treatment, MD, Blood, Program, Solution, Pharmaceutical industry, Hospital, Medical imaging

CENTER VALLEY, Pa., Nov. 3, 2022 /PRNewswire/ -- Olympus Corporation, a global medical technology company committed to making people's lives healthier, safer, and more fulfilling, announced that the Centers for Medicare and Medicaid Services (CMS) will increase payment rates for the iTind™ procedure performed in the hospital-based outpatient department (HOPD) and Ambulatory Surgical Center (ASC). The proposed rule was finalized and announced on November 1, 2022, and rates will be effective January 1, 2023.

Key Points: 
  • The proposed rule was finalized and announced on November 1, 2022, and rates will be effective January 1, 2023.
  • The final CMS CY2023 Outpatient Prospective Payment System (OPPS) Rule increases payment rates for code C9769 covering the iTind procedure in HOPD and ASC facilities.
  • The rule changes are as follows:
    "We applaud CMS for recognizing the value of the iTind procedure.
  • Clinical evidence demonstrates that the iTind procedure safely and effectively relieves symptoms while preserving sexual function.

New Randomized Controlled Study Published in JAMA Demonstrates the Value of Clinical Decision Support Tools in Preventing Acute Kidney Injury in Patients Undergoing Coronary Angiography

Retrieved on: 
Tuesday, November 1, 2022
MPH, AKI, Cardiac catheterization, Population, American Medical Association, Percutaneous coronary intervention, Blood transfusion, Acute kidney injury, Doctor of Philosophy, Clinical study design, Efficiency, TMP, TPS, Hospital, Risk, Physician, FACC, JAMA, TIS, TMC, Technology, THO, Divisional Railway Hospital, Golden Rock, University, Assistant, Journal, Multimedia, University of Missouri–Kansas City School of Medicine, Precision medicine, Peritoneal dialysis, Solution, CDS, PCI, Cardiology, Laboratory, Medical device, Medical imaging, Pharmaceutical industry, MD, Feedback, Patient, Terumo, Medicine

SOMERSET, N.J., Nov. 1, 2022 /PRNewswire/ -- A new study published in JAMA[1] demonstrated that patients at high risk for acute kidney injury (AKI), the most common complication of percutaneous coronary intervention (PCI), had a significant reduction in AKI when cardiologists used Terumo Health Outcomes' (THO's) ePRISM clinical decision support (CDS) platform.

Key Points: 
  • "The three-year randomized study shows the benefits of the THO ePRISM platform to strategically target the high-risk portion of the population.
  • Using tools like ePRISM to improve outcomes represents the future of precision medicine in routine clinical practice."
  • [1]Effect of Clinical Decision Support With Audit and Feedback on Prevention of Acute Kidney Injury in Patients Undergoing Coronary Angiography: A Randomized Clinical Trial.
  • Published in The Journal of the American Medical Association (JAMA) Sept. 6, 2022; Volume 328, Number 9.

AMRA Medical at AASLD 2022: Premier MRI Technology and Informatics for The Full Continuum of Liver Disease

Retrieved on: 
Wednesday, October 26, 2022
Medical Supplies, Biotechnology, Professional Services, Health, General Health, Venture Capital, Biometrics, Health Technology, Medical Devices, Research, Science, BCP, Disease, Therapy, Informatics, Liver disease, Risk, Clinical study design, Non-alcoholic fatty liver disease, NAFLD, Patient, Research, Multimedia, MRI, Technology, Mass, Sarcopenia, CEO, Cirrhosis, Liver, Lists of diseases, 2021 Essex County Council election, Frailty, Chronic liver disease, FDA, Conditional sentence, Solution, Scan, Magnetic resonance imaging, Medical imaging, Dietary supplement, Dentistry

AMRA Medical , and their collaborators, will present seven abstracts along the whole disease progression line of chronic liver disease, with studies involving individuals with early liver disease (non-alcoholic fatty liver disease; NAFLD) to cirrhosis to liver transplant.

Key Points: 
  • AMRA Medical , and their collaborators, will present seven abstracts along the whole disease progression line of chronic liver disease, with studies involving individuals with early liver disease (non-alcoholic fatty liver disease; NAFLD) to cirrhosis to liver transplant.
  • View the full release here: https://www.businesswire.com/news/home/20221026005321/en/
    AMRA Medicals MRI-based technology and informatics are featured in seven abstracts accepted for presentation at The Liver Meeting 2022 the worlds must-attend hepatology meeting.
  • Two abstracts involving individuals with early liver disease and the potential to risk stratify based on muscle composition will be presented.
  • Attend the abstract presentations or visit our booth #731 to learn more about the utility of AMRAs technology in liver disease research and in the clinic.

Wellbeing Digital to Participate at this Years’ Wonderland Miami Conference

Retrieved on: 
Tuesday, October 25, 2022
Research, Finance, Professional Services, Small Business, Biotechnology, Health, General Health, Other Science, Science, Therapy, Politics, Conference, MEDI, Patient, Drug development, Depression, Research, SQ2, Pain, FRA, Ketamine, NEO, CEO, OTC, Clinical study design, Pharmaceutical industry

Wellbeing Digital Sciences Inc. (Wellbeing or the Company) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate at this years Wonderland Miami Conference taking place on November 3 to November 5, 2022 at the Mana Wynwood Convention Centre.

Key Points: 
  • Wellbeing Digital Sciences Inc. (Wellbeing or the Company) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate at this years Wonderland Miami Conference taking place on November 3 to November 5, 2022 at the Mana Wynwood Convention Centre.
  • Wonderland is one of the worlds largest conferences in the psychedelic medicine sector.
  • For more information about the conference, or to schedule a one-on-one meeting with Wellbeing management team, please send an email to Natalie Dolphin at [email protected] .
  • Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research.